Immunocal
70 International "Method of Use"
Patents.
Before
we look at the actual patents that have been registered for Immunocal,
it is critically important to recognize a few factors that set our
product apart from ANY
OTHER NEUTRACEUTICAL on the market.
You
can see that we make specific reference to the fact that the Immunocal
Patents are "METHOD OF
USE" Patents.
Since most of the population knows what a "PATENT" is, this does not
have to be explained.
However, most of the population DOES
NOT KNOW what a "Method
of Use" Patent is. So, here is the
difference;
Just
about anything can be patented by anyone, for things like; a new
invention, a new way to manufacture something or a new blend of
ingredients, all for a particular product that someone has created.
These are very good patents for protecting something, so that it cannot
be legally reproduced by someone else.
"Method
of Use" Patents on the other hand are normally restricted
to drugs
because they actually state a specific result which has been proven
scientifically, with Medical
Community Standards of Research needed before they can be
registered.
This is what
sets Immunotec Research and Immunocal apart from the rest of the
products and companies.
This
is what allows you to rest assured that you are consuming the BEST PRODUCT
available for YOUR
IMMUNE SYSTEM, guaranteeing YOU that by consuming
Immunocal, you are increasing your critical intracellular glutathione. |
|
|
|
|
North
& South America
Argentina |
Canada |
Chile |
Mexico |
United States |
Europe
to Africa
|
Austria |
Czech Republic |
Denmark |
Europe |
Germany |
|
Israel |
Italy |
Norway |
South Africa |
Spain |
Sweden |
United Kingdom |
Asia
- Australia & New Zealand
Australia |
China |
Japan |
New Zealand |
Singapore |
South Korea |
Taiwan |
|
Please CLICK the country flag above to view our Patents
| Note: the original
patents and research were done in Canada and the USA. You will notice
some countries have patented all, while others have chosen to
be
conservative and only patent either the; Anti-cancer, HIV treatment or
Immune Response patents, with the exception of Singapore. More patents
will come, we are just getting started internationally... |
|
|
Immunotec
Inc. congratulates Dr. Luc Montagnier for winning the 2008
Nobel Prize in Medicine for his 1984 discovery, with Françoise
Barré–Sinoussi, of the Human Immunodeficiency Virus (HIV).
 Drs.
Montagnier and
Barré-Sinoussi first understood that HIV “impaired the immune system
because of massive virus replication and cell damage to lymphocytes.”
Their seminal work set the stage for understanding the biology of the
disease and current modalities of treatment. In addition, it led to
development of methods of diagnosis and blood screening that has
mitigated the spread of the disease.
Dr. Montagnier and his colleagues edited Oxidative Stress in Cancer,
AIDS, and Neurodegenerative Diseases, devoting an entire
chapter to a paper co-authored by Immunotec founding scientist Dr.
Gustavo Bounous, entitled;
Nutriceutical Modulation of Glutathione with a Humanized Native Milk
Serum Protein Isolate, Immunocal: Application in AIDS and
Cancer,
|
| With all
this proof and recognition, it is hard to imagine this is also a home
business opportunity. |
|
|
